ClinicalTrials.gg
RecruitingNCT05933707SEVUpdated Jul 17, 2026

Small Extracellular Vesicles and Insulin Action

An interventional study of People with Metabolically Unhealthy Obesity - Low Calorie Diet in Obesity, Insulin Resistance and Metabolically Healthy Obesity, sponsored by Washington University School of Medicine. Recruiting at 1 site in United States. Open to participants aged 25 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-17.

Primary conditionObesity, Metabolically BenignRegistry: ObesityReclassifiedWhy we changed it
Registry
Obesity — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity, Metabolically Benign
Why
  1. The study's listed conditions name Obesity, Metabolically Benign, a narrower term within Obesity.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Washington University School of Medicine · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Jun 2023; still recruiting 3 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
72
Allocation
Non-randomized
Ages
25 Years to 55 Years
Sex
All
01

Study summary

The goals of this research study are to: 1) understand why some people with obesity are protected from developing conditions such as type 2 diabetes and cardiovascular disease while others are more likely to develop obesity-related conditions; 2) assess the effect of small extracellular vesicles (sEVs also called exosomes), obtained from human participants, on metabolic function in cultured cells and in mice.

Read the detailed description

Insulin resistance is commonly associated with obesity and is a major contributor to the development of obesity-related metabolic diseases, including nonalcoholic fatty liver disease, the metabolic syndrome, and type 2 diabetes (T2D). Most persons with obesity are "metabolically unhealthy" (MUO), often defined by having insulin resistance and the metabolic syndrome. However, a subset of people with obesity are metabolically healthy (MHO) and protected from the adverse metabolic effects of excess adiposity. The mechanisms that determine the differences in metabolic health between people with MUO and MHO are not unclear. This project will examine the effects of plasma and adipose tissue small extracellular vesicles (sEVs) on multi-organ insulin action. The investigators will isolate sEVs from subcutaneous abdominal adipose tissue biopsies and blood samples obtained from human participants with MHO, MUO or who are metabolically healthy and lean (MHL) and examine the effects of these sEVs on insulin resistance in muscle, liver and fat cells in culture and on multi-organ insulin sensitivity in lean and obese mice. The investigators will also identify differences in the potential bioactive molecules, namely miRNA and bioactive lipids, that are carried by sEVs. The results from this study will help determine whether plasma or adipose tissue sEVs in people who are MHL, MHO, or MUO are involved in regulating liver, muscle and adipose tissue insulin sensitivity. These results could identify novel pathways that regulate metabolic health in people and provide the foundation for exploring the potential of sEVs as a therapeutic target to prevent and treat the metabolic complications of obesity.

02

Conditions studied

  • Obesity
  • Insulin Resistance
  • Metabolically Healthy Obesity
  • Obesity, Metabolically Benign

Browse trials for

Keywords

  • Obesity
  • Weight Loss
  • Exosomes
  • Extracellular vesicles
03

In context

Obesity, Metabolically Benign Reclassified

27 studies on the registry are indexed under Obesity, Metabolically Benign; 8 are open to participants now.

This study's planned enrollment of 72 is above the median of 60 across 17 interventional studies indexed under Obesity, Metabolically Benign.

Browse Obesity, Metabolically Benign studies →

Lead sponsor

Washington University School of Medicine is the lead sponsor of 1,806 studies on the registry; 271 are open to participants now.

Of its 329 completed or terminated interventional studies of FDA-regulated products, 216 (66%) have results posted.

Compared within Obesity, Metabolically Benign, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Obesity. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
25 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Metabolically healthy lean subjects must have a ≥18.5 and ≤24.9 kg/m²; Subjects with obesity must have a BMI ≥30.0 and ≤50.0 kg/m²
  • Metabolically healthy lean and people with metabolically healthy obesity must have intrahepatic triglyceride (IHTG) content ≤5%; fasting plasma glucose concentration \<100 mg/dl, 2-hr oral glucose tolerance plasma glucose concentration \<140 mg/dl, A 1C () ≤5.6% and HOMA-IR \<2.5.
  • People with metabolically unhealthy obesity must have intrahepatic triglyceride (IHTG) content ≥5.6%; HOMA-IR ≥2.5, and HbA1c 5.7%-6.4%, or fasting plasma glucose concentration ≥100 mg/dl, or 2-hr oral glucose tolerance test (OGTT) plasma glucose concentration ≥140 mg/dl.

Exclusion criteria

Exclusion Criteria:

  • History of diabetes, liver disease other than NAFLD or other serious diseases,
  • Consume excessive amounts of alcohol (>21 units/week for men and >14 units/week for women),
  • Take medications that could affect the study outcome measures, engage in regular exercise (>120 min/week),
  • Are pregnant or lactating
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
72 participants (estimated)

Study arms

  • No intervention
    Metabolically healthy lean - Baseline testing only

    Metabolically healthy lean - Lean individuals that have good glucose (sugar) control (defined as normal fasting glucose, glucose tolerance and hemoglobin A1c), normal insulin sensitivity (defined as Homeostatic Model Assessment of Insulin Resistance \[HOMA-IR\] \<2.5) and normal intrahepatic triglyceride (fat) levels. Dietary intervention - None.

  • No intervention
    People with Metabolically Healthy Obesity - Baseline testing only

    People with Metabolically Healthy Obesity - Persons with obesity that have good glucose (sugar) control, normal insulin sensitivity and normal intrahepatic triglyceride (fat) levels. Dietary intervention - None.

  • Experimental
    People with Metabolically Unhealthy Obesity - Low Calorie Diet

    People with Metabolically Unhealthy Obesity - Persons with obesity with plasma glucose and intrahepatic triglyceride (fat) levels higher than recommended in combination with insulin resistance (defined as HOMA-IR ≥2.5). Dietary intervention - Low calorie diet.

    Behavioral: People with Metabolically Unhealthy Obesity - Low Calorie Diet

Interventions

  • BehavioralPeople with Metabolically Unhealthy Obesity - Low Calorie Diet

    Consumption of a low-calorie diet with caloric intake reduced by \~25% to achieve \~10% weight loss in about 4 to 5 months.

    Also known as: Dietary weight loss

06

What researchers measure

Primary outcomes

  1. Effect of exosomes on insulin sensitivity in cultured cells

    Exosomes obtained from the plasma and adipose tissue of metabolically healthy lean participants, and participants with metabolically healthy or metabolically unhealthy obesity will be tested in cultured cells and mice to determine their effect on insulin sensitivity.

    Time frame: Baseline only (cross-sectional comparison of metabolically healthy lean, and of people with metabolically healthy or metabolically unhealthy obesity).

  2. Change in the effect of exosomes on insulin sensitivity

    Exosomes obtained from the plasma and adipose tissue of participants with metabolically unhealthy obesity before and after 10% weight loss will be tested in cultured cells and mice to determine their effect on insulin sensitivity.

    Time frame: Before and after ~10% weight loss (~4-5 months) in people with metabolically abnormal obesity

Secondary outcomes

  1. Differences in the content of microRNAs within exosomes obtained from plasma and adipose tissue

    Exosomes obtained from the plasma and adipose tissue of metabolically healthy lean participants, and participants with metabolically healthy or metabolically unhealthy obesity will be analyzed to determine their microRNA composition.

    Time frame: Baseline only (cross-sectional comparison of metabolically healthy lean, and of people with metabolically healthy or metabolically unhealthy obesity).

  2. Differences in the content of lipids within exosomes obtained from plasma and adipose tissue

    Exosomes obtained from the plasma and adipose tissue of metabolically healthy lean participants, and participants with metabolically healthy or metabolically unhealthy obesity will be analyzed to determine their lipid composition.

    Time frame: Baseline only (cross-sectional comparison of metabolically healthy lean, and of people with metabolically healthy or metabolically unhealthy obesity).

  3. Changes in the content of microRNAs within exosomes obtained from plasma and adipose tissue

    Exosomes obtained from the plasma and adipose tissue of metabolically unhealthy obesity before and after weight loss will be analyzed to determine changes in their microRNA content after weight loss.

    Time frame: Before and after ~10% weight loss (~4-5 months) in people with metabolically abnormal obesity

  4. Changes in the content of lipids within exosomes obtained from plasma and adipose tissue

    Exosomes obtained from the plasma and adipose tissue of metabolically unhealthy obesity before and after weight loss will be analyzed to determine changes in their lipid content after weight loss.

    Time frame: Before and after ~10% weight loss (~4-5 months) in people with metabolically abnormal obesity

  5. Insulin sensitivity

    Whole-body insulin sensitivity will be assessed by using the hyperinsulinemic-euglycemic clamp procedure

    Time frame: Baseline only (cross-sectional comparison of metabolically healthy lean, and people with metabolically healthy or metabolically unhealthy obesity).

  6. Change in insulin sensitivity

    Whole-body insulin sensitivity will be assessed by using the hyperinsulinemic-euglycemic clamp procedure

    Time frame: Before and after ~10% weight loss (~4-5 months) in people with metabolically abnormal obesity

  7. Fat mass and fat free mass

    Fat mass and fat free mass will be assessed using dual-energy x-ray absorptiometry (DXA)

    Time frame: Baseline only (cross-sectional comparison of metabolically healthy lean, and people with metabolically healthy or metabolically unhealthy obesity).

  8. Change in fat mass and fat free mass

    Fat mass and fat free mass will be assessed using dual-energy x-ray absorptiometry (DXA)

    Time frame: Before and after 10% weight loss (~4-5 months) in people with metabolically abnormal obesity

  9. Abdominal adipose tissue volumes

    Abdominal subcutaneous and intra-abdominal adipose tissue volumes will be assessed by magnetic resonance imagining (MRI)

    Time frame: Baseline only (cross-sectional comparison of metabolically healthy lean, and people with metabolically healthy or metabolically unhealthy obesity).

  10. Change in abdominal adipose tissue volumes

    Abdominal subcutaneous and intra-abdominal adipose tissue volumes will be assessed by magnetic resonance imagining (MRI)

    Time frame: Before and after ~10% weight loss (~4-5 months) in people with metabolically abnormal obesity

  11. Intra-hepatic triglyceride content

    Intra-hepatic triglyceride content will be assessed by magnetic resonance techniques

    Time frame: Baseline only (cross-sectional comparison of metabolically healthy lean, and people with metabolically healthy or metabolically unhealthy obesity).

  12. Change in intra-hepatic triglyceride content

    Intra-hepatic triglyceride content will be assessed by magnetic resonance techniques

    Time frame: Before and after ~10% weight loss (~4-5 months) in people with metabolically abnormal obesity

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Currently there is no plan to share individual participant data.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2023 (actual). Primary completion is estimated for Jun 2028, 59 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2023
First posted
Jul 6, 2023
StartActual
Jun 14, 2023
Primary completionEst.
Jun 1, 2028
CompletionEst.
Aug 31, 2028
Last update
Jul 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05933707
Responsible party
Sponsor
First posted
Jul 6, 2023
Start date
Jun 14, 2023
Primary completion
Jun 1, 2028 (estimated)
Completion
Aug 31, 2028 (estimated)
Last update
Jul 17, 2026

Study contacts

Kyle Timmons
Contact
nutritionresearch@wustl.edu
3142731879
Beth Henk
Contact
bhenk@wustl.edu
3143628250
Dmitri Samovski, PhD
principal investigator · Washington University School of Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion